Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) Director Keith S. Manchester sold 368,052 shares of the firm’s stock in a transaction that occurred on Tuesday, September 24th. The stock was sold at an average price of $11.62, for a total transaction of $4,276,764.24. Following the transaction, the director now directly owns 1,412,126 shares of the company’s stock, valued at $16,408,904.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Roivant Sciences Price Performance
NASDAQ:ROIV opened at $11.48 on Friday. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05. Roivant Sciences Ltd. has a 12-month low of $8.24 and a 12-month high of $13.24. The stock’s 50 day moving average price is $11.50 and its two-hundred day moving average price is $11.08. The firm has a market capitalization of $8.48 billion, a price-to-earnings ratio of 2.27 and a beta of 1.25.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The business had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. During the same quarter in the prior year, the business earned ($0.38) EPS. The firm’s revenue for the quarter was up 155.1% on a year-over-year basis. On average, analysts anticipate that Roivant Sciences Ltd. will post -1.14 earnings per share for the current year.
Institutional Trading of Roivant Sciences
Analysts Set New Price Targets
ROIV has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Piper Sandler lifted their target price on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Bank of America upped their target price on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Thursday, September 19th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.39.
Read Our Latest Report on Roivant Sciences
Roivant Sciences Company Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
See Also
- Five stocks we like better than Roivant Sciences
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Transportation Stocks Investing
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Are Penny Stocks a Good Fit for Your Portfolio?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.